Moolec Science SA (MLECW) — SEC Filings

Overview

Moolec Science SA (MLECW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 31, 2025: Moolec Science SA filed a Form 6-K on December 31, 2025, reporting information for the month of December 2025. This filing includes a press release as Exhibit 99.1 and is incorporated by reference into the company's Form S-8 registration statement (Registration No. 333-282263). The company's princip

Sentiment Summary

Across 43 filings, the sentiment breakdown is: 2 bearish, 41 neutral. The dominant filing sentiment for Moolec Science SA is neutral.

Filing Type Overview

Moolec Science SA (MLECW) has filed 39 6-K, 2 20-F, 1 SC 13D, 1 SC 13D/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (43)

• Moolec Science SA Files 6-K Report — 6-K · Dec 31, 2025 Risk: low
  Moolec Science SA filed a Form 6-K on December 31, 2025, reporting information for the month of December 2025. This filing includes a press release as Exhibit 9
• Moolec Science Undergoes Major Restructuring, Faces Going Concern Doubts — 20-F · Dec 29, 2025 Risk: high
  Moolec Science SA's 20-F filing for the fiscal year ended June 30, 2025, highlights a transformative period marked by a significant Business Combination. On Jun
• 6-K Filing — 6-K · Dec 16, 2025
• Moolec Science Adjourns Shareholder Meeting to Dec 16 — 6-K · Dec 12, 2025 Risk: low
  Moolec Science SA announced the adjournment of its Extraordinary General Meeting of Shareholders to December 16, 2025. The meeting was originally scheduled for
• 6-K Filing — 6-K · Nov 28, 2025
• Moolec Science SA Receives Nasdaq Determination Letter — 6-K · Nov 20, 2025 Risk: medium
  On November 14, 2025, Moolec Science SA received a determination letter from Nasdaq. This Form 6-K filing is incorporated by reference into the company's existi
• Moolec Science SA Faces Potential Dispute with INVIM — 6-K · Oct 21, 2025 Risk: medium
  Moolec Science SA announced on October 2, 2025, that it received a notice of alleged breach from INVIM Corporativo S.L. regarding an Assignment and Assumption A
• Moolec Science SA Files September 2025 6-K Report — 6-K · Sep 12, 2025 Risk: low
  Moolec Science SA filed a Form 6-K on September 12, 2025, reporting on its activities for the month of September 2025. The filing includes a press release dated
• Moolec Science SA Executes 1-for-10 Reverse Stock Split — 6-K · Aug 12, 2025 Risk: low
  Moolec Science SA announced a reverse stock split of its Ordinary Shares, effective May 14, 2025. The consolidation ratio is ten-to-one, meaning shareholders re
• Moolec Science SA Announces Board Changes — 6-K · Jun 18, 2025 Risk: low
  Moolec Science SA announced a new composition of its Board of Directors and its committees on June 16, 2025. This announcement is incorporated by reference into
• Moolec Science Acquires Stake in Bioceres Crop Solutions — 6-K · Jun 17, 2025 Risk: medium
  Moolec Science SA, a company focused on animal-free protein production, announced on June 17, 2025, that it has entered into a definitive agreement to acquire a
• Moolec Science SA Calls Extraordinary General Meeting — 6-K · Jun 16, 2025 Risk: low
  Moolec Science SA announced an Extraordinary General Meeting of Shareholders to be held in June 2025. The company, a public limited liability company registered
• Moolec Science SA Calls Shareholder Meeting for BCA Approval — 6-K · Jun 4, 2025 Risk: medium
  Moolec Science SA has issued a 6-K filing on June 4, 2025, announcing an Extraordinary General Meeting of shareholders scheduled for June 16, 2025. The meeting
• Moolec Science SA Files 6-K Report — 6-K · May 13, 2025 Risk: low
  Moolec Science SA filed a Form 6-K on May 13, 2025, reporting a press release dated May 12, 2025. The filing includes a signature from Chief Financial Officer J
• Moolec Science SA Announces Reverse Stock Split — 6-K · Apr 29, 2025 Risk: medium
  Moolec Science SA announced on April 29, 2025, that it will implement a reverse stock split of its ordinary shares, par value U.S.$0.01 per share. This action w
• Moolec Science SA Calls Extraordinary Shareholder Meeting — 6-K · Apr 23, 2025 Risk: low
  Moolec Science SA (NASDAQ: MLEC) announced it will hold an Extraordinary General Meeting of Shareholders on April 22, 2025. The purpose of this meeting is to di
• Moolec Science SA Files 6-K Report — 6-K · Apr 21, 2025 Risk: low
  Moolec Science SA filed a Form 6-K on April 21, 2025, to report a press release dated April 21, 2025. The filing includes Exhibit 99.1, which is the press relea
• Moolec Science SA Files 6-K on Business Combination — 6-K · Apr 18, 2025 Risk: low
  Moolec Science SA filed a Form 6-K on April 18, 2025, incorporating information about its business combination. This filing includes details on the structure of
• Moolec Science SA Files 6-K Report — 6-K · Apr 16, 2025 Risk: low
  Moolec Science SA filed a Form 6-K on April 16, 2025, reporting for the period ending December 31, 2024. This filing incorporates by reference the company's reg
• Moolec Science SA Directors Resign — 6-K · Apr 9, 2025 Risk: medium
  Moolec Science SA announced on April 7, 2025, that Gastón Paladini and Esteban Corley will resign from their positions on the Board of Directors, effective Apri
• Moolec Science SA Calls Shareholder Meeting for Office Transfer — 6-K · Apr 8, 2025 Risk: medium
  Moolec Science SA has issued a notice for an Extraordinary General Meeting of shareholders to be held on April 22, 2025, in Luxembourg. The primary agenda item
• Moolec Science SA Gets Nasdaq Listing Exception — 6-K · Apr 4, 2025 Risk: medium
  Moolec Science SA (NASDAQ: MLEC) announced on April 4, 2025, that it has been granted a temporary exception by Nasdaq to remain listed on the exchange. This fil
• Moolec Science Receives Nasdaq Staff Determination Letter — 6-K · Mar 14, 2025 Risk: medium
  Moolec Science SA (NASDAQ: MLEC) received a Nasdaq Staff Determination Letter on March 14, 2025, indicating non-compliance with listing requirements. The compan
• Moolec Science SA Files 6-K with Financial Statements — 6-K · Jan 31, 2025 Risk: low
  Moolec Science SA filed a Form 6-K on January 31, 2025, incorporating unaudited interim condensed consolidated financial statements as of September 30, 2024, an
• Moolec Science SA Schedules Shareholder Meetings — 6-K · Dec 30, 2024 Risk: low
  Moolec Science SA announced its 2024 Annual Shareholders' Meeting and Extraordinary General Meeting of Shareholders will be held on December 27, 2024. The infor
• Moolec Science SA Calls Shareholder Meetings for Dec 27 — 6-K · Dec 13, 2024 Risk: medium
  Moolec Science SA has issued a 6-K filing on December 13, 2024, announcing its Annual General Meeting and Extraordinary General Meeting scheduled for December 2
• Moolec Science SA Files 2024 Annual Report — 20-F · Oct 30, 2024 Risk: medium
  Moolec Science SA filed its annual report on Form 20-F for the fiscal year ended June 30, 2024. The company, incorporated in Luxembourg, is listed with SEC file
• Moolec Science SA Files 6-K Report — 6-K · Oct 16, 2024 Risk: low
  Moolec Science SA filed a Form 6-K on October 16, 2024, to report a press release dated the same day. The filing does not contain specific financial figures or
• Moolec Science SA Files FY24 Business Update — 6-K · Oct 7, 2024 Risk: low
  Moolec Science SA filed a 6-K report on October 7, 2024, including a press release dated October 2, 2024, detailing its Fiscal Year 2024 Business Update. The fi
• Moolec Science SA Files 6-K Report — 6-K · Sep 13, 2024 Risk: low
  Moolec Science SA filed a Form 6-K on September 13, 2024, to report a press release dated the same day. The press release, filed as Exhibit 99.1, contains infor
• Moolec Science SA Files 6-K with Argentine Press Release — 6-K · Aug 9, 2024 Risk: low
  Moolec Science SA filed a Form 6-K on August 9, 2024, reporting an Argentinean Press Release dated August 6, 2024. The filing includes Exhibit 99.1, which is th
• Moolec Science SA Files 6-K Report — 6-K · Jul 15, 2024 Risk: low
  Moolec Science SA filed a Form 6-K on July 15, 2024, to report a press release dated July 15, 2024. The filing does not contain specific financial figures or op
• Moolec Science SA Files 6-K with Interim Financials — 6-K · Jun 28, 2024 Risk: low
  Moolec Science SA filed a Form 6-K on June 28, 2024, to report its unaudited interim condensed consolidated financial statements as of March 31, 2024, and June
• Moolec Science SA Reports Q3 FY24 Business Update — 6-K · May 31, 2024 Risk: low
  Moolec Science SA filed a Form 6-K on May 31, 2024, to report its Third Quarter Fiscal Year 2024 Business Update, dated May 30, 2024. The filing includes a pres
• Moolec Science SA Files 6-K Report — 6-K · May 24, 2024 Risk: low
  Moolec Science SA filed a Form 6-K on May 24, 2024, reporting its activities for May 2024. The filing includes a press release dated May 23, 2024. Gastón Paladi
• Moolec Science SA Files April 2024 Report — 6-K · Apr 30, 2024 Risk: low
  Moolec Science SA filed a Form 6-K on April 30, 2024, reporting its activities for the month of April 2024. The filing includes a press release dated April 30,
• Moolec Science SA Files 6-K Report — 6-K · Apr 23, 2024 Risk: low
  Moolec Science SA filed a Form 6-K on April 23, 2024, reporting a press release dated April 22, 2024. The filing is a report of a foreign private issuer and inc
• Moolec Science SA Files Interim Financial Report — 6-K · Apr 18, 2024 Risk: low
  Moolec Science SA filed a Form 6-K on April 18, 2024, to report its unaudited interim condensed consolidated financial statements as of December 31, 2023, and J
• Gaston Paladini & Biotech Co LLC Acquire Stake in Moolec Science SA — SC 13D · Apr 17, 2024 Risk: medium
  On April 17, 2024, Gaston Paladini and Biotech Co LLC filed an SC 13D, reporting beneficial ownership of Moolec Science SA. The filing indicates a change in own
• Bioceres Group PLC Amends Moolec Science SA Filing — SC 13D/A · Apr 10, 2024 Risk: low
  Bioceres Group PLC, through Gloria Montaron Estrada, filed an amendment (No. 1) to its Schedule 13D on April 10, 2024, concerning Moolec Science SA. The filing
• Moolec Science SA Announces 2023 Annual Meeting Date — 6-K · Mar 12, 2024 Risk: low
  Moolec Science SA announced its 2023 Annual Shareholders' Meeting will be held on March 28, 2024. The meeting will cover standard corporate business, including
• Moolec Science SA Files 6-K for Shareholder Meeting Notice — 6-K · Feb 26, 2024 Risk: low
  Moolec Science SA, a foreign private issuer, filed a Form 6-K on February 26, 2024, to report a Convening Notice for its Annual General Meeting of Shareholders.
• Moolec Science Files Q3 2023 Unaudited Financials — 6-K · Jan 22, 2024
  Moolec Science SA, a foreign private issuer, filed a 6-K on January 22, 2024, to provide its unaudited interim condensed consolidated financial statements for t

Risk Profile

Risk Assessment: Of MLECW's 40 recent filings, 1 were flagged as high-risk, 12 as medium-risk, and 27 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Valeria Falottico
• Alejandro Antalich
• José López Lecube
• José López Lecube
• Gastón Paladini
• Esteban Corley
• Gaston Paladini
• Matthew S. Poulter
• Gloria Montaron Estrada

Industry Context

Moolec Science operates in the agricultural technology and biotechnology sectors, focusing on developing and commercializing novel food ingredients and crop solutions. The industry is characterized by significant R&D investment, long development cycles, and evolving regulatory landscapes, particularly concerning genetically modified organisms (GMOs). Key trends include the demand for sustainable and alternative protein sources, precision agriculture, and the integration of advanced breeding and fermentation technologies.

Top Tags

press-release (12) · 6-K (10) · foreign-private-issuer (8) · corporate-governance (8) · shareholder-meeting (8) · regulatory-filing (6) · filing-update (6) · filing (5) · sec-filing (4) · foreign-issuer (3)

Key Numbers

• Ordinary Shares outstanding: 10,891,761 — As of June 30, 2025, after a 10-to-1 reverse stock split
• Nominal value per Ordinary Share: US$0.10 — New par value after the reverse stock split on May 14, 2025
• Business Combination Closing Date: June 16, 2025 — Date of consummation of the reverse acquisition
• Outstanding shares present at EGM: 77% — Percentage of shares present at the Extraordinary General Meeting on June 16, 2025
• Votes in favor of Business Combination: 98% — Percentage of votes cast in favor of the transaction at the EGM
• Reverse Stock Split Effective Date: May 14, 2025 — Date Moolec Science (Luxembourg) made effective a ten-to-one reverse stock split
• Redomiciliation Date: May 22, 2025 — Date Moolec changed jurisdiction from Luxembourg to the Cayman Islands
• Business Combination Agreement Date: April 16, 2025 — Date the Business Combination Agreement was entered into
• Reverse Stock Split Ratio: 1-for-10 — Share consolidation effective May 14, 2025
• SEC File Number: 001-41586 — Identifies the company's filing with the SEC.
• Form F-3 Registration Number: 333-283113 — Indicates incorporation by reference into a specific registration statement.
• Form S-8 Registration Number: 333-282263 — Indicates incorporation by reference into a specific registration statement.
• Reporting Period End Date: 20241231 — The period for which this 6-K report is filed
• Filing Date: 20250416 — The date the 6-K was filed with the SEC
• Fiscal Year End: 0630 — Indicates the end of the reporting period for financial statements.

Related Companies

BIOX · MLEC

Frequently Asked Questions